A statement released earlier today by Noble Financial about ESSA Pharma (OTCMKTS:EPIX) bumps the target price to $9.00
- Updated: February 17, 2017
Boasting a price of $2.35, ESSA Pharma (OTCMKTS:EPIX) traded 0.00% even on the day. With the last stock price close up 2.21% from the two hundred day average, compared with the S&P 500 Index which has increased 0.06% over the date range. ESSA Pharma has recorded a 50-day average of $2.08 and a two hundred day average of $2.30. Volume of trade was down over the average, with 0 shares of EPIX changing hands under the typical 4,773
Noble Financial bumped up the target of ESSA Pharma (OTCMKTS:EPIX) to $9.00 stating a potential upside of 2.83%.
With a total market value of $0, ESSA Pharma has with a one year low of $1.50 and a one year high of $3.89 .
Brief Synopsis About ESSA Pharma (OTCMKTS:EPIX)
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.